Pharmacokinetics of oxaliplatin in humans

@article{Ehrsson2002PharmacokineticsOO,
  title={Pharmacokinetics of oxaliplatin in humans},
  author={Hans Ehrsson and Inger Wallin and Jeffrey Yachnin},
  journal={Medical Oncology},
  year={2002},
  volume={19},
  pages={261-265}
}
Oxaliplatin is a novel platinum complex used for the treatment of metastatic colorectal carcinoma. The pharmacokinetics of the free fraction of oxaliplatin in blood were evaluated in 10 patients given 85 mg/m2 of oxaliplatin using an infusion time of 2 h. Blood samples were collected during and after the infusion and immediately placed on ice. The samples were ultrafiltrated centripetally and the concentration of oxaliplatin in the ultrafiltrate was determined by liquid chromatography in… Expand
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction
TLDR
The comparable platinum exposure early after administration in conjunction with the lack of acute toxicity do not support a dose reduction of oxaliplatin in patients with markedly elevated bilirubin concentrations, but a larger number of patients must be examined before valid dose recommendations can be derived. Expand
Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function
TLDR
Oxali Platin pharmacokinetics are altered in patients with renal impairment, but a corresponding increase in oxaliplatin-related toxicities is not observed. Expand
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion
TLDR
The systemic exposure of oxaliplatin measured after HIPEC using a selective analytical technique is considerably lower than previously reported results obtained by atomic absorption spectroscopy. Expand
Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives
TLDR
The product of AUCp and the toxicity factor is a useful predictor of the degree of toxicity of oxaliplatin as has been observed with other platinum drugs. Expand
Dose-banding studies on oxaliplatin
TLDR
Dose-banding with the +10% maximum deviation was selected as the most promising dosing scheme for oxaliplatin and safety and efficacy of vii dose- banding schemes was demonstrated by comparing the simulated PK characteristics gained from the ex vivo model. Expand
BIOTRANSFORMATION OF THE ANTINEOPLASTIC DRUG OXALIPLATIN: IMPORTANCE FOR EFFECTS AND SIDE EFFECTS
Oxaliplatin is a platinum-based cytostatic drug. It is used in combination with 5fluorouracil and leucovorin for palliative and adjuvant treatment of metastatic colorectal cancer. TheExpand
Oxaliplatin: a review of approved uses
TLDR
Oxaliplatin has proven beneficial in the treatment of CRC and can currently be regarded as one of the three most important chemotherapeutic drugs used in the Treatment of both metastatic disease and adjuvant therapy in stage II/III after resection. Expand
Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.
TLDR
The rate of the reaction of oxaliplatin with three sulphur-containing compounds was faster for oxali platin than what is previously known for cisplatin, which may be important with respect to differences in the cellular effects of cisplin and oxali Platin treatment. Expand
Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols
TLDR
The bioactivity of peritoneal perfusates ex vivo is a useful parameter for evaluating the actual cytotoxic potential of OX and its derivatives used in HIPEC over time, overcoming important limitations and disadvantages associated with respective drug monitoring only. Expand
New insights into the biotransformation and pharmacokinetics of oxaliplatin.
Oxaliplatin is used primarily in the treatment of metastatic colorectal cancer. In this minireview, we discuss potentially important biotransformation pathways in light of its short eliminationExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 12 REFERENCES
Oxaliplatin pharmacokinetics during a four-hour infusion.
TLDR
On the basis of the simulation of the plasma levels and the urinary excretion of platin following the long-term administration of oxaliplatin as a constant-rate and a chronomodulated infusion, additional analyses are warranted to fully characterize the pharmacokinetics of the drug in these settings. Expand
Clinical pharmacokinetics of oxaliplatin: a critical review.
TLDR
These results indicate that the additive/synergistic antitumor activity observed with oxaliplatin, 5-fluorouracil, and irinothecan is not due to major alterations in drug exposure, and the enhanced efficacy is likely to be mechanistically based. Expand
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
TLDR
This study failed to elicit any relationship between moderate renal impairment and the acute toxicity associated with oxaliplatin, and results are in agreement with the in vitro data concerning the extensive binding of oxali Platin to plasma proteins and RBCs. Expand
Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
TLDR
It is demonstrated that in the first hours after its infusion, oxaliplatin, in addition to other Pt compounds, is present in plasma and urine and that Pt is bound to albumin, gamma-globulins, and hemoglobin. Expand
Biotransformations of oxaliplatin in rat blood in vitro
TLDR
Pt‐dach complexes appeared to be taken up better by RBCs than cisplatin or carboplatin, and the hydrophobicity of most of the Pt‐daches appeared to correlate with uptake, however, factors other than the dach carrier ligand and hydrophOBicity clearly influence uptake. Expand
Pharmacokinetics of cisplatin and its monohydrated complex in humans.
TLDR
The pharmacokinetics of cisplatin and its cytotoxic hydrolysis product cis-diammineaquachloroplatinum(II) ion (monohydrated complex) were investigated in seven patients after they received a 1-h infusion of cis platin in normal saline at 100 mg/m2 and it was concluded that the significant amounts of the monohydratedcomplex present in blood are due to the fraction already present in the administered dose and to the fractions formed in blood. Expand
Oxaliplatin clinical activity: a review.
TLDR
Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin. Expand
Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate--implications for quantitative analysis.
TLDR
The monohydrated complex was found to be formed to a small extent when cisplatin was added to plasma and found applicable if the samples were stored at 0 degree C and ultracentrifuged within 1 h. Expand
Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
TLDR
The data suggest that intracellular conversion of oxaliplatin to Pt(dach)Cl2 makes only a minor contribution to Pt-DNA adduct formation and the resultant cytotoxicity of oxalaplatin. Expand
Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate.
TLDR
A post-column derivatization method has been developed and used to evaluate the plasma concentration of cisplatin and its monohydrated form in a patient. Expand
...
1
2
...